EsoCap has announced that scientists from the University of Greifswald published exciting data demonstrating that a novel drug delivery technology enables targeted and long-lasting local therapy of the esophagus for the first time (Krause et al., J Control Release 2020; 327:1-7).
In contrast to tablets, capsules or viscous fluids, which are known for short esophageal transit times, the EsoCap system ensures a targeted and long-lasting drug delivery in the esophagus. The team at the University of Greifswald demonstrated the feasibility of their novel delivery concept, which is based on application of a mucosal adhesive foil, in 12 healthy volunteers and showed that the system is well accepted and adheres to the esophageal mucosa for at least 15 minutes.
“This finding fundamentally alters the therapeutic options in the field of esophageal diseases“ said Prof. Werner Weitschies, head of the Biopharmaceutics group at the Center of Drug Absorption and Transport. “These results are ground-breaking and form the basis for a promising new approach to local drug therapies for patients with a wide range of esophageal diseases, who currently have no suitable treatment options.”